Montgomery Street

Asure Software, Inc. Announces Pricing of Public Offering of Common Stock

Retrieved on: 
Thursday, August 17, 2023
Attention, Montgomery Street, Capital market, Telephone, ASUR, Enterprise file synchronization and sharing, Security agreement, Sale, Suite, Prospectus, Equity capital markets, Investment, Human resource management, Form, Security (finance), LP, HCM, Roth Capital Partners, Capital Group Companies, Stifel, Asure Software, Incorporated

The offering consists of 3,333,333 newly issued shares being sold by Asure at a public offering price of $12.00 per share.

Key Points: 
  • The offering consists of 3,333,333 newly issued shares being sold by Asure at a public offering price of $12.00 per share.
  • The gross proceeds to Asure from this offering are expected to be approximately $40 million, before deducting underwriting discounts and commissions and other estimated offering expenses payable by Asure.
  • Asure has granted the underwriters a 30-day over-allotment option to purchase up to an additional 500,000 shares of common stock from Asure at the same price.
  • Asure intends to use the net proceeds received from the sale of its common stock for general corporate purposes.

Asure Software, Inc. Announces Public Offering of Common Stock

Retrieved on: 
Wednesday, August 16, 2023
Attention, Montgomery Street, Telephone, ASUR, Enterprise file synchronization and sharing, Security agreement, Sale, Suite, Prospectus, Equity capital markets, Investment, Human resource management, Form, Security (finance), LP, HCM, Capital Group Companies, Stifel, Asure Software, Incorporated

AUSTIN, Texas, Aug. 16, 2023 (GLOBE NEWSWIRE) -- Asure Software, Inc. (NASDAQ: ASUR), a leading provider of cloud-based Human Capital Management (HCM) software solutions, today announced that it intends to offer and sell newly issued shares of its common stock in an underwritten public offering.

Key Points: 
  • AUSTIN, Texas, Aug. 16, 2023 (GLOBE NEWSWIRE) -- Asure Software, Inc. (NASDAQ: ASUR), a leading provider of cloud-based Human Capital Management (HCM) software solutions, today announced that it intends to offer and sell newly issued shares of its common stock in an underwritten public offering.
  • In connection with the proposed offering, Asure is expected to grant the underwriters a 30-day over-allotment option to purchase up to an additional 15% of the number of shares of common stock sold by Asure in the offering.
  • Asure intends to use the net proceeds received from the sale of its common stock for general corporate purposes.
  • The shares of common stock are being offered pursuant to an effective shelf registration statement on Form S-3 (File No.

Benitec Biopharma Inc. Announces Closing of $30 Million Underwritten Public Offering

Retrieved on: 
Friday, August 11, 2023
Janus, Exercise, Benitec Biopharma, Attention, Montgomery Street, RNA-dependent RNA polymerase, Bangladesh Securities and Exchange Commission, RNA, Sale, Prospectus, Form, Security (finance)

The pre-funded warrants are immediately exercisable until exercised in full at an exercise price of $0.0001 per share of common stock.

Key Points: 
  • The pre-funded warrants are immediately exercisable until exercised in full at an exercise price of $0.0001 per share of common stock.
  • The common warrants are immediately exercisable at an exercise price of $3.86 per share of common stock and will expire on the fifth anniversary of such initial exercisable date.
  • In addition, Benitec has granted the underwriter a 30-day option to purchase an additional 2,331,606 shares of common stock and/or common warrants to purchase up to an additional 2,331,606 shares of common stock at the public offering price, less discounts and commissions.
  • The aggregate gross proceeds to Benitec from the public offering were approximately $30.9 million (after giving effect to the 458,134 additional shares of common stock and 458,134 additional common warrants sold pursuant to the underwriter’s partial exercise of its over-allotment option), prior to deducting underwriting discounts, commissions and other estimated offering expenses.

Benitec Biopharma Inc. Announces Pricing of $30 Million Underwritten Public Offering

Retrieved on: 
Wednesday, August 9, 2023
Janus, Exercise, Benitec Biopharma, Attention, Montgomery Street, RNA-dependent RNA polymerase, RNA, Sale, Prospectus, Form, Security (finance)

The pre-funded warrants, if any, will be immediately exercisable until exercised in full at an exercise price of $0.0001 per share of common stock.

Key Points: 
  • The pre-funded warrants, if any, will be immediately exercisable until exercised in full at an exercise price of $0.0001 per share of common stock.
  • The offering is expected to close on August 11, 2023, subject to customary closing conditions.
  • In addition, Benitec has granted the underwriter a 30 day option to purchase an additional 2,331,606 shares of common stock and/or common warrants to purchase up to an additional 2,331,606 shares of common stock at the public offering price, less discounts and commissions.
  • The aggregate gross proceeds to Benitec from the public offering are expected to be approximately $30 million, prior to deducting underwriting discounts, commissions and other estimated offering expenses.

Acumen Announces Pricing of Upsized $130 Million Public Offering

Retrieved on: 
Wednesday, July 19, 2023
ABOS, Attention, Montgomery Street, Telephone, BofA Securities, Sale, Suite, Prospectus, TEL, Form S-3, Citigroup, Form, Security (finance), AD, Broadridge Financial Solutions, Acumen, Stifel

The gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Acumen, are expected to be approximately $130 million.

Key Points: 
  • The gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Acumen, are expected to be approximately $130 million.
  • In addition, Acumen has granted the underwriters a 30-day option to purchase up to an additional 2,516,128 shares of its common stock at the public offering price, less underwriting discounts and commissions.
  • BofA Securities, Citigroup and Stifel are acting as bookrunners for the public offering.
  • Before you invest, you should read the prospectus in the registration statement and related prospectus supplement for more complete information about Acumen and this offering.

Apogee Therapeutics, Inc. Announces Closing of Upsized Initial Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares

Retrieved on: 
Tuesday, July 18, 2023
Exercise, Attention, Montgomery Street, Lexington Avenue, Floor, Apsis, The 8th Floor, TD, Telephone, Jefferies, Atopic dermatitis, Guggenheim, Sale, Chronic obstructive pulmonary disease, Suite, Prospectus, Jefferies Group, SAN, Madison Avenue, Security (finance), Therapy, Guggenheim Partners, Stifel, Incorporated

The aggregate gross proceeds to Apogee from the offering were approximately $345 million before deducting underwriting discounts and commissions and other offering expenses payable by Apogee.

Key Points: 
  • The aggregate gross proceeds to Apogee from the offering were approximately $345 million before deducting underwriting discounts and commissions and other offering expenses payable by Apogee.
  • All of the shares were offered by Apogee.
  • The shares began trading on the Nasdaq Global Market on July 14, 2023 under the ticker symbol “APGE.”
    Jefferies, TD Cowen, Stifel and Guggenheim Securities acted as joint book-running managers for the offering.
  • Registration statements relating to these securities have been filed with the Securities and Exchange Commission and became effective on July 13, 2023.

Acumen Pharmaceuticals Announces Proposed Public Offering of Common Stock

Retrieved on: 
Monday, July 17, 2023
ABOS, Attention, Montgomery Street, Telephone, BofA Securities, Research, Sale, Chemistry, Suite, TEL, Form S-3, Citigroup, Form, Security (finance), AD, Broadridge Financial Solutions, Pharmaceutical industry, Acumen, Stifel

All of the shares to be sold in the offering are to be sold by Acumen.

Key Points: 
  • All of the shares to be sold in the offering are to be sold by Acumen.
  • In connection with the offering, Acumen intends to grant the underwriters a 30-day option to purchase up to an additional $15 million of shares of its common stock.
  • The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
  • BofA Securities, Citigroup and Stifel are acting as bookrunners for the public offering.

Apogee Therapeutics, Inc. Announces Pricing of Upsized Initial Public Offering

Retrieved on: 
Thursday, July 13, 2023
Attention, Montgomery Street, Lexington Avenue, Floor, Apsis, The 8th Floor, TD, Telephone, Jefferies, Atopic dermatitis, Guggenheim, Sale, Chronic obstructive pulmonary disease, Suite, Prospectus, Jefferies Group, SAN, Madison Avenue, Security (finance), Therapy, Guggenheim Partners, Stifel, Incorporated

SAN FRANCISCO and WALTHAM, Mass., July 13, 2023 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (Nasdaq: APGE), a biotechnology company advancing differentiated biologics for the treatment of atopic dermatitis, chronic obstructive pulmonary disease, and other inflammatory and immunology indications (“Apogee” or the “Company”), today announced the pricing of its upsized initial public offering of 17,650,000 shares of common stock at a public offering price of $17.00 per share.

Key Points: 
  • SAN FRANCISCO and WALTHAM, Mass., July 13, 2023 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (Nasdaq: APGE), a biotechnology company advancing differentiated biologics for the treatment of atopic dermatitis, chronic obstructive pulmonary disease, and other inflammatory and immunology indications (“Apogee” or the “Company”), today announced the pricing of its upsized initial public offering of 17,650,000 shares of common stock at a public offering price of $17.00 per share.
  • The aggregate gross proceeds to Apogee from the offering are expected to be approximately $300 million before deducting underwriting discounts and commissions and other offering expenses payable by Apogee.
  • In addition, Apogee has granted the underwriters a 30-day option to purchase up to an additional 2,647,500 shares of common stock at the initial public offering price, less underwriting discounts and commissions.
  • Jefferies, TD Cowen, Stifel and Guggenheim Securities are acting as joint book-running managers for the offering.

IGM Announces Closing of Upsized Public Offering and Concurrent Private Placement and Full Exercise of the Underwriters’ Option to Purchase Additional Shares

Retrieved on: 
Monday, July 3, 2023
Exercise, Attention, Montgomery Street, IGM, Telephone, Jefferies, BofA Securities, Guggenheim, Equity, Sale, Suite, Prospectus, Jefferies Group, Form, Madison Avenue, Security (finance), Guggenheim Partners, Stifel, Incorporated

All of the shares in the public offering were sold by IGM and delivered to purchasers on June 26, 2023, other than with respect to 5,625,000 shares of non-voting common stock, delivery of which occurred on July 3, 2023.

Key Points: 
  • All of the shares in the public offering were sold by IGM and delivered to purchasers on June 26, 2023, other than with respect to 5,625,000 shares of non-voting common stock, delivery of which occurred on July 3, 2023.
  • The public offering and the concurrent private placement resulted in gross proceeds for IGM of $120.0 million, before deducting the underwriting discounts and commissions and estimated offering expenses payable by IGM.
  • BofA Securities, Jefferies, Stifel, and Guggenheim Securities acted as joint book-running managers for the public offering.
  • A final prospectus supplement and accompanying prospectus relating to the public offering was filed with the SEC and may be accessed for free through the SEC’s website at www.sec.gov.

CorMedix Inc. Announces Pricing of $40 Million Public Offering of Common Stock and Pre-Funded Warrants

Retrieved on: 
Thursday, June 29, 2023
Vesey Street, Attention, Montgomery Street, The 8th Floor, Telephone, SEC filing, Research, Sale, RBC Capital Markets, Suite, Prospectus, Equity capital markets, Form, Security (finance)

The total gross proceeds from the offering to the Company are expected to be approximately $40 million, before deducting the underwriting discounts and commissions and other offering expenses.

Key Points: 
  • The total gross proceeds from the offering to the Company are expected to be approximately $40 million, before deducting the underwriting discounts and commissions and other offering expenses.
  • In addition, CorMedix granted the underwriters a 30-day option to purchase up to an additional 1,500,093 shares of its common stock at the public offering price of $4.00 per share, less underwriting discounts and commissions.
  • RBC Capital Markets, Truist Securities and JMP Securities, a Citizens Company, are acting as book-running managers for the offering.
  • CorMedix intends to use the net proceeds from the public offering for general corporate purposes, commercialization efforts, research and development, and working capital and general expenditures.